Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathway

Chinese Journal of Cancer

Volumn 28, Issue 6, 2009, Pages

  Wang, Ling ^a   Liu, Li Hong ^a   Shan, Bao En ^a   Zhang, Chao ^a   Sang, Mei Xiang ^a   Li, Jia ^b  

^a Medical University   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; Celecoxib; MDA MB 231 cells; NF B pathway

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CELECOXIB; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROSTAGLANDIN E2; SYNAPTOTAGMIN I;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INCUBATION TIME; MONOTHERAPY; PLOIDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 79955772654     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Morris GJ, Mitchell EP. Higher incidence of aggressive breast cancers in African-American women: a review [J]. J Natl Med Assoc, 2008, 100(6): 698-702.
2. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006 [J]. CA Cancer J Clin, 2006, 56(3): 168-183.
3. Rostom A, Dubé C, Lewin G, et al. Nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force [J]. Ann Intern Med, 2007, 146(5): 376-389.
4. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2 [J]. Annu Rev Med, 2007, 58: 239-252.
5. Mustafa A, Kruger WD. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer [J]. Clin Cancer Res, 2008, 14 (15): 4935-4942.
6. Ahmed KM, Cao N, Li JJ. HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer [J]. Anticancer Res, 2006, 26 (6B): 4235-4243.
7. Howe LR. Inflammation and breast cancer. Cyclooxygenase/ prostaglandin signaling and breast cancer [J]. Breast Cancer Res, 2007, 9(4): 210.
8. Singh P, Mittal A. Current status of COX-2 inhibitors [J]. Mini Rev Med Chem, 2008, 8(1): 73-90.
9. Futagami S, Suzuki K, Hiratsuka T, et al. Chemopreventive effect of celecoxib in gastric cancer [J]. Inflammopharmacology, 2007, 15(1): 1-4.
10. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase-2 (COX-2) blockade: results of case control studies [J]. Subcell Biochem, 2007, 42: 193-212.
11. Wu G, Yi J, Di F, et al. Celecoxib inhibits proliferation and induces apoptosis via cyclooxygenase-2 pathway in human pancreatic carcinoma cells [J]. J Huazhong Univ Sci Technolog Med Sci, 2005, 25 (1): 42-44.
12. Wu GS, Zou SQ, Liu ZR, et al. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines [J]. World J Gastroenterol, 2003, 9(6): 1302-1306.
13. Wu T, Leng J, Han C, et al. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells [J]. Mol Cancer Ther, 2004, 3(3): 299-307.
14. Dandekar DS, Lopez M, Carey RI, et al. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and-9 in prostate cancer cells [J]. Int J Cancer, 2005, 115 (3): 484-492.
15. Mazumder S, Plesca D, Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis [J]. Methods Mol Biol, 2008, 414: 13-21.
16. Kuribayashi K, Mayes PA, El-Deiry WS. What are caspases 3 and 7 doing upstream of the mitochondria? [J] Cancer Biol Ther, 2006, 5(7): 763-765.
17. Dolcet X, Llobet D, Pallares J, et al. NF-kB in development and progression of human cancer [J]. Virchows Arch, 2005, 446(5): 475-482.
18. Inoue J, Gohda J, Akiyama T, et al. NF-kappaB activation in development and progression of cancer [J]. Cancer Sci, 2007, 98(3): 268-274.
19. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors [J]. FASEB J, 2001, 15(12): 2057-2072.
20. Subhashini J, Mahipal SV, Reddanna P. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro [J]. Cancer Lett, 2005, 224(1): 31-43.